Y Intercept (Hong Kong) LTD Immatics N.V. Call Options Transaction History
Y Intercept (Hong Kong) LTD
- $1.37 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding IMTX
# of Institutions
82Shares Held
91.5MCall Options Held
201KPut Options Held
109K-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.7MShares$72.4 Million0.04% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$46.3 Million1.77% of portfolio
-
Suvretta Capital Management, LLC New York, NY9.14MShares$45 Million1.8% of portfolio
-
Wellington Management Group LLP Boston, MA8.58MShares$42.3 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY7.28MShares$35.9 Million0.39% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $376M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...